science
Pharma and Large Biotech Firms Complete 32 Deals Worth $123 Billion in First Half of 2026
Pharmaceutical and large biotech firms spent about $123 billion on 32 deals of $1 billion or more in the six months through June 22, 2026. The total exceeds the $112 billion spent on 26 similar deals in all of 2025.
etftrends.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Pharmaceutical companies and some large biotech firms completed 32 acquisitions of biotech companies valued at $1 billion or more in the six months ending June 22, 2026, Stat reported. The buyers spent approximately $123 billion on those transactions. The pace surpassed the full-year 2025 total.
In that calendar year, pharmaceutical companies struck 26 deals of $1 billion or more and spent $112 billion in all, according to the same data. The figures show buyers closing more transactions in half the time it took the prior year. Stat published the numbers in an article by reporter Allison DeAngelis on June 22, 2026.
Transparency
1 source · single source
CorroborationModerate · 1 source
